Discovery of Cellular Mechanisms Could Open Door to More Effective Anti-Aging Therapies
UTSW experts: Gaps in clinical whole exome sequencing at major commercial labs indicative of larger issue
BioMarin Pharmaceutical Inc, a global biotechnology company announced that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three years of data from an ongoing phase 1/2 study to evaluate safety and efficacy of investigational AAV gene therapy, valoctocogene roxaparvovec, for severe hemophilia A. This is the second article published by the NEJM on valoctocogene roxaparvovec.
Researchers from ETH Zurich and the National University of Singapore have developed a new kind of bandage that helps blood to clot and doesn’t stick to the wound. This marks the first time that scientists have combined both properties in one material.
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies.